Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group by Christian H. Geisler, Arne Kolstad, Anna Laurell, Niels S. Andersen, Lone B. Pedersen, Mats Jerkeman, Mikael Eriksson, Marie Nordström, Eva Kimby, Anne Marie Boesen, Outi Kuittinen, Grete F. Lauritzsen, Herman Nilsson-Ehle, Elisabeth Ralfkiær, Måns Åkerman, Mats Ehinger, Christer Sundström, Ruth Langholm, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Peter Brown, Erkki Elonen, and Blood Volume 112(7):2687-2693 October 1, 2008 ©2008 by American Society of Hematology
Survival. Survival. Event-free survival (A) and overall survival (B) of patients of NLG protocols MCL-1 and MCL-2, respectively, based on intention-to-treat of all included patients. (C) Progression-free survival of protocols MCL-1 and MCL-2, respectively, of responders who completed treatment. Christian H. Geisler et al. Blood 2008;112:2687-2693 ©2008 by American Society of Hematology
Event-free survival. Event-free survival. EFS according to the proportion of lymphoma cells that expressed Ki-67 (A), lymphoma growth pattern (B), cytologic variant (C), and IPI 0-II versus IPI III-5 (D). Christian H. Geisler et al. Blood 2008;112:2687-2693 ©2008 by American Society of Hematology